What is the 13F Pro Quality Score for ECVT?

13F Pro ranks Ecovyst Inc. (ECVT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ECVT's current score at https://13fpro.ai/research/ECVT (free sign-up required for the full ranking).

Which hedge funds own the most ECVT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ECVT include Rubric Capital Management, BlackRock,, DIMENSIONAL FUND ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ECVT as soon as new 13F filings post.

Where does 13F Pro source ECVT data?

All Ecovyst Inc. fundamentals and ownership data come directly from SEC EDGAR. Ecovyst Inc. files with the SEC under CIK 1708035. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ECVT in?

Ecovyst Inc. (ECVT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ECVT research updated on 13F Pro?

ECVT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ecovyst Inc.(ECVT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1708035 ECVT stock profile & AI dashboard →

13F Pro Quality Score

36.6/100

Rank #2,095 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

48.3/100

Profitability

19.0/100

Balance Sheet

22.9/100

Earnings Quality

30.0/100

Free Cash Flow

55.3/100

Institutional Flow

17.4/100

Revenue Scale

43.7/100

Dilution Risk

49.3/100

ECVT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Ecovyst Inc. (ECVT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ECVT at 36.6/100 on a 32-signal composite quality model, placing it at rank #2,095 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (17.4) and profitability (19.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 49.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Ecovyst Inc. reports quarterly revenue of $215.0M, net income of $4.3M, an operating margin of 5.8%. Top institutional holders of ECVT by reported 13-F value include Rubric Capital Management, BlackRock,, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. ECVT trades on the NYSE exchange and files with the SEC under CIK 1708035. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ECVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ecovyst Inc. directly from SEC EDGAR. Ecovyst Inc.'s 13F Pro composite quality score has ranged between 8 and 58 since 2021, currently 36.6 — an improving long-term trajectory across 53 quarterly and live scoring snapshots.

✦

Fun facts about Ecovyst Inc.

Quirks, history, and lore behind ECVT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty chemicals and materials company · listed on the NYSE · headquartered in Malvern, Pennsylvania · small-cap.
2
The Numbers
Annual revenue in the range of $500–600 million — not a household name, but quietly essential to refining and industrial processes worldwide.
3
The History
The company traces its roots back decades through PQ Group Holdings, which was taken private and later restructured before re-emerging as a focused catalyst and services spinoff around 2021.
4
The Secret
Its core business is making silica-based catalysts and providing sulfuric acid regeneration services — unglamorous chemistry that keeps oil refineries running cleanly.
5
The Lore
The company rebranded to signal a greener future — the "Eco" in its name nods to sustainability, while its catalyst technology helps refiners produce cleaner fuels with lower emissions.
6
The Giveaway
Ticker ECVT, born from the breakup of PQ Group Holdings — a Pennsylvania specialist in zeolyst catalysts and acid regeneration that quietly makes gasoline a little less dirty.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$215.0M

Net Income

Q1 2026

$4.3M

Free Cash Flow

Q1 2026

$2.8M

Operating Margin

Q1 2026

5.8%

D/E Ratio

Q1 2026

0.68

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+20.9% YoY

$723.5MFY 2025

FY18 $527.7MFY22 $820.2MFY24 $598.3MFY25 $723.5M

Net Income

-968.9% YoY

$-71.1MFY 2025

FY18 $58.3MFY22 $73.7MFY24 $-6.7MFY25 $-71.1M

Operating Income

-23.8% YoY

$64.9MFY 2025

FY18 $69.8MFY22 $104.4MFY24 $85.1MFY25 $64.9M

EPS (Diluted)

-916.7% YoY

$-0.61FY 2025

FY18 $0.43FY22 $0.55FY24 $-0.06FY25 $-0.61

Total Assets

-30.0% YoY

$1.26BFY 2025

FY18 $4.33BFY22 $1.88BFY24 $1.80BFY25 $1.26B

Total Debt

-54.9% YoY

$392.6MFY 2025

FY18 $2.12BFY22 $883.9MFY24 $869.6MFY25 $392.6M

Op. Cash Flow

-6.4% YoY

$140.3MFY 2025

FY18 $248.6MFY22 $186.6MFY24 $149.9MFY25 $140.3M

Metric	FY 2025	FY 2024	FY 2022	FY 2018	FY 2017	FY 2016
Revenue	$723.5M +20.9%	$598.3M -27.1%	$820.2M +55.4%	$527.7M -64.2%	$1.47B +38.3%	$1.06B
Net Income	$-71.1M -968.9%	$-6.7M -109.0%	$73.7M +26.4%	$58.3M +1.2%	$57.6M +172.2%	$-79.7M
Operating Income	$64.9M -23.8%	$85.1M -18.4%	$104.4M +49.5%	$69.8M -57.9%	$165.9M +103.4%	$81.5M
EPS (Diluted)	$-0.61 -916.7%	$-0.06 -110.9%	$0.55 +27.9%	$0.43 -17.3%	$0.52 +550.2%	$-0.12
Total Assets	$1.26B -30.0%	$1.80B -4.4%	$1.88B -56.5%	$4.33B -2.0%	$4.42B +3.7%	$4.26B
Total Debt	$392.6M -54.9%	$869.6M -1.6%	$883.9M -58.3%	$2.12B -6.8%	$2.28B -11.7%	$2.58B
Operating Cash Flow	$140.3M -6.4%	$149.9M -19.7%	$186.6M -25.0%	$248.6M +50.5%	$165.2M +34.6%	$122.7M

AI Insight: ECVT Financial Trends

Debt cut in half to $393M in Q4 2025, but revenue volatility and net income swings persist through Q1 2026.

• Total debt halved from $870M (Q2 2024) to $393M (Q4 2025), signaling major deleveraging; maintained at $393M through Q1 2026.

• Operating cash flow remained positive across all periods, ranging $10M–$60M, providing cushion despite earnings swings.

• Revenue volatile: ranged $106M–$255M over eight quarters with no sustained growth trend; Q1 2026 at $215M near upper range.

⚠ Net income erratic: swung from +$14M (Q3 2024) to -$79M (Q3 2025) to +$6M (Q4 2025), suggesting underlying operational instability.

⚠ Equity contracted 20% from $717M (Q2 2024) to $575M (Q1 2026); combined with debt cuts, signals substantial asset reduction or writedowns.

AI Insight: ECVT Ratio Trends

Leverage has halved but profitability is deeply erratic, with TTM net margin deeply negative at -8.1% despite a positive Q1 2026 quarter.

• D/E ratio fell sharply from 1.42 in Q3 2025 to 0.65 in Q4 2025, holding at 0.68 in Q1 2026 — a meaningful deleveraging step.

• Operating margin swung from -0.6% in Q1 2025 to 16.2% in Q3 2025, then contracted to 5.8% in Q1 2026, showing high volatility.

• TTM net profit margin stands at -8.1%, dragged by a severe -49.0% NPM spike in Q3 2025, masking recent quarterly stabilization.

⚠ ROIC dropped to -0.2% in Q1 2025 and sits at only 5.2% in Q1 2026 — well below the 8.1% TTM level; recovery consistency is unproven.

⚠ Recurring large one-off losses (Q4 2024: -20.4% NPM; Q3 2025: -49.0% NPM) suggest unpredictable below-the-line items requiring scrutiny.

⚠ D/E improvement to 0.68 warrants monitoring — confirm it reflects permanent debt reduction rather than temporary balance-sheet timing.

Get alerted when ECVT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ecovyst Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ECVT

Rubric Capital Management LP
$117.5M9,136,067 sh
BlackRock, Inc.
$112.3M8,734,220 sh
DIMENSIONAL FUND ADVISORS LP
$83.6M6,498,654 sh
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC
$69.6M5,413,862 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$67.4M5,244,406 sh
VANGUARD CAPITAL MANAGEMENT LLC
$64.0M4,977,580 sh
BROWN ADVISORY INC
$62.3M4,842,174 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$62.1M4,829,034 sh
FMR LLC
$57.5M4,467,425 sh
Allspring Global Investments Holdings, LLC
$49.8M3,798,389 sh

Fund	Value	Shares
Rubric Capital Management LP	$117.5M	9,136,067
BlackRock, Inc.	$112.3M	8,734,220
DIMENSIONAL FUND ADVISORS LP	$83.6M	6,498,654
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC	$69.6M	5,413,862
VANGUARD PORTFOLIO MANAGEMENT LLC	$67.4M	5,244,406
VANGUARD CAPITAL MANAGEMENT LLC	$64.0M	4,977,580
BROWN ADVISORY INC	$62.3M	4,842,174
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$62.1M	4,829,034
FMR LLC	$57.5M	4,467,425
Allspring Global Investments Holdings, LLC	$49.8M	3,798,389

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ECVT on your watchlist

Track score changes the day Ecovyst Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ECVT a good stock to buy?

13F Pro's AI-powered analysis of Ecovyst Inc. (ECVT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ECVT are available on the ECVT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ECVT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ECVT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ecovyst Inc.'s investment landscape.